Dr. Lal PathLabs Q4/FY26 Results, ₹4 Dividend, Strategic Acquisitions

Dr. Lal PathLabs Ltd's Board of Directors approved the audited Standalone & Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The board recommended a final dividend of ₹4/- per equity share (40% on face value of ₹10/- each) for FY26, with June 26, 2026, as the record date. Additionally, the company announced the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), making it a Wholly Owned Subsidiary. Dr. Lal PathLabs also approved the incorporation of a new Wholly Owned Subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE, signaling international expansion. Key management re-appointments include (Hony) Brig. Dr. Arvind Lal as Executive Chairman and Whole-Time Director, and Mr. Rajit Mehta as Non-Executive Independent Director. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. The company also re-appointed M/s Ernst & Young LLP as Internal Auditors and M/s A.G. Agarwal & Associates as Cost Auditors for FY26-27, and allotted 82,750 Equity Shares under its ESOP 2022.